Advertisement
Research

Genetic Evidence Suggests Insomnia Drives Inflammation, Not the Other Way Around, Study Finds

A genome-wide analysis of more than 450,000 UK Biobank participants found 125 shared genetic loci between insomnia and C-reactive protein, with evidence pointing toward insomnia raising inflammation rather than the reverse

A genetic analysis of DNA variants linked to insomnia and inflammation points to a shared biological pathway

A large genetic analysis has found that insomnia and chronic low-grade inflammation are far more intertwined than previously understood — and that the sleep disorder appears to be the one driving the relationship, not the other way around.

The study, by Farah Abou Daya, Jesse Valliere, Matthew Maher, and Richa Saxena of Massachusetts General Hospital and the Broad Institute, was published in the journal Sleep under the title "Genetic pleiotropy highlights immune mechanisms that link insomnia and C-reactive protein." The team drew on UK Biobank data, comparing 130,611 people with insomnia against 327,375 controls, and found that C-reactive protein (CRP) — a standard blood marker of systemic inflammation used throughout medicine to flag infection, cardiovascular risk, and chronic disease activity — was measurably elevated in the insomnia group.

Finding the Genetic Overlap

Rather than stopping at that observational association, which could be explained by countless lifestyle or health confounders, the researchers turned to genetic correlation analysis and identified 125 genomic regions where variants influencing insomnia risk overlap with variants influencing CRP levels. That degree of shared genetic architecture — genetic pleiotropy, in technical terms — indicates the two traits are connected at a biological level deeper than simple co-occurrence in the same patients.

To tease out which trait is more likely driving the other, the team applied Mendelian randomization, a method that uses genetic variants as natural experiments to approximate cause and effect in ways standard observational studies cannot. That analysis found stronger statistical support for a path running from insomnia liability to higher CRP (inverse variance weighted β = 0.299; P = 5.52 × 10⁻¹⁰) than for the reverse path, in which inflammation would be the trigger for poor sleep.

What the Shared Pathways Point To

Pathway analysis of the overlapping genetic regions implicated several biological processes already of interest to inflammation researchers: immune signaling, cellular senescence — the process by which aging or damaged cells stop dividing but linger and secrete inflammatory signals — and programmed cell death. Together, these point toward a plausible mechanism in which chronic sleep disruption perturbs the immune system at a cellular level rather than simply correlating with it through shared risk factors like obesity or stress.

Limitations Worth Noting

The authors are careful to flag several constraints on how far the findings can be pushed. Insomnia status in the UK Biobank was self-reported rather than confirmed through clinical sleep studies, which introduces the kind of misclassification common in large population datasets. The researchers also note that residual genetic pleiotropy and sample overlap between the insomnia and CRP datasets cannot be fully ruled out as alternative explanations for the Mendelian randomization result, a standard caveat for this type of genetic-instrument analysis. Mendelian randomization strengthens the case for causation beyond what observational data alone can show, but it does not amount to direct experimental proof.

What This Means for Patients

This research adds to a growing case that insomnia is not merely a symptom of poor health but potentially a contributor to it, through a specific and partly mapped biological channel: low-grade systemic inflammation that has independently been linked to cardiovascular disease, metabolic dysfunction, and other chronic conditions. If the causal direction holds up in future work, treating chronic insomnia could turn out to carry benefits that extend well beyond daytime alertness.

For now, the findings are genetic and population-level, not a basis for new clinical guidance. But patients with persistent insomnia — particularly those who also carry other inflammation-linked conditions, such as cardiovascular disease or autoimmune disorders — may want to raise the connection with their physician, since addressing sleep could plausibly be one more lever in managing inflammatory risk, pending the confirmatory studies the authors say are still needed.

Advertisement